NASDAQ:HURA

TuHURA Biosciences Q1 2025 Earnings Results & Report

TuHURA Biosciences logo
$1.41 +0.01 (+0.71%)
As of 01:26 PM Eastern
This is a fair market value price provided by Massive. Learn more.

TuHURA Biosciences missed analyst earnings expectations in its Q1 2025 results, released May 15, 2025. The company reported EPS of -$0.15 versus the -$0.13 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

TuHURA Biosciences EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.13
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

TuHURA Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TuHURA Biosciences Q1 2025 Earnings FAQ

TuHURA Biosciences (NASDAQ:HURA) reported earnings of -$0.15 per share for Q1 2025, missing the consensus estimate of -$0.13. The report was announced on Thursday, May 15, 2025.

TuHURA Biosciences Earnings Headlines

Pentagon magnet restrictions take effect January 1, 2027
A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel
See More TuHURA Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TuHURA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TuHURA Biosciences and other key companies, straight to your email.

About TuHURA Biosciences

TuHURA Biosciences (NASDAQ:HURA) is a clinical-stage biotechnology company developing immunotherapies for cancer. Its research focuses on treatments intended to stimulate the immune system and address mechanisms that allow tumors to evade immune attack.

The company’s pipeline includes IFx-2.0, an investigational intratumoral immunotherapy being studied for use with checkpoint inhibitors, as well as antibody programs targeting immune-regulating pathways. TuHURA has no marketed products, and its candidates remain in development.

TuHURA became a publicly traded company following its 2024 merger with Kintara Therapeutics. The company is based in Tampa, Florida, and is led by President and Chief Executive Officer James Bianco.

View TuHURA Biosciences Profile